Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Brachytherapy. 2023 Mar-Apr;22(2):132-138. doi: 10.1016/j.brachy.2022.10.007. Epub 2022 Dec 29.
This study was conducted to evaluate the clinical efficacy and safety of computed tomography (CT)-guided I implantation in the treatment of recurrent or metastatic pelvic malignant tumor.
This retrospective study analyzed the data of 30 patients with recurrent and metastatic pelvic malignant tumor who were treated with CT-guided I implantation between January 2016 and December 2020. Disease control rate, objective remission rate, overall survival (OS), pain relief rate, quality of life score, and complications were evaluated after the followup.
Median followup was 20.1 (7-30) months. Disease control rate was 86.67% at 6 months. Objective response rates at 1, 3, and 6 months were 36.67%, 60%, and 56.67%, respectively. OS rates at 12 and 24 months were 76.67% (23/30) and 33.33% (10/30), respectively. Progression-free survival rates at 12 and 24 months were 63.33% (19/30) and 33.33% (10/30), respectively. Postoperative pain relief rate was 86.67% (26/30). There were no major bleeding, pelvic abscess, intestinal fistula, intestinal perforation, and other serious complications.
CT-guided I seed implantation in the treatment of patients with pelvic malignant tumor is a simple operation and less traumatic and can improve patients' quality of life and reduce tumor load.
本研究旨在评估计算机断层扫描（CT）引导下碘 125 放射性粒子植入治疗复发性或转移性盆腔恶性肿瘤的临床疗效和安全性。
本回顾性研究分析了 2016 年 1 月至 2020 年 12 月期间 30 例复发性和转移性盆腔恶性肿瘤患者接受 CT 引导下碘 125 放射性粒子植入治疗的数据。随访后评估疾病控制率、客观缓解率、总生存期（OS）、疼痛缓解率、生活质量评分和并发症。
中位随访时间为 20.1（7-30）个月。6 个月时疾病控制率为 86.67%。1、3 和 6 个月时的客观缓解率分别为 36.67%、60%和 56.67%。12 个月和 24 个月的 OS 率分别为 76.67%（23/30）和 33.33%（10/30）。12 个月和 24 个月的无进展生存率分别为 63.33%（19/30）和 33.33%（10/30）。术后疼痛缓解率为 86.67%（26/30）。无大出血、盆腔脓肿、肠瘘、肠穿孔等严重并发症。
CT 引导下碘 125 放射性粒子植入治疗盆腔恶性肿瘤是一种简单的操作，创伤较小，可以提高患者的生活质量，减轻肿瘤负荷。
